Literature DB >> 26294723

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Alessandra Tedeschi1, Davide Rossi2, Marina Motta3, Giulia Quaresmini4, Marianna Rossi5, Marta Coscia6, Antonella Anastasia7, Fausto Rossini8, Agostino Cortelezzi9, Guido Nador10, Lydia Scarfò11, Roberto Cairoli12, Anna Maria Frustaci13, Daniela Dalceggio3, Paola Picardi13, Lorenzo De Paoli2, Ester Orlandi5, Alessandro Rambaldi4, Massimo Massaia6, Gianluca Gaidano2, Marco Montillo13.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukemia; cyclophosphamide; elderly; ofatumumab; pentostatin

Mesh：

Substances：

Year:  2015        PMID： 26294723      PMCID： PMC4666341          DOI： 10.3324/haematol.2015.132035

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Authors:  Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

3.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

4.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

5.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Authors:  Tait Shanafelt; Mark C Lanasa; Timothy G Call; Anne W Beaven; Jose F Leis; Betsy LaPlant; Deborah Bowen; Michael Conte; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Clive S Zent
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

7.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

Authors:  A C Rawstron; N Villamor; M Ritgen; S Böttcher; P Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; M Geuna; P A S Evans; Y Natkunam; S E Coutre; E D Avery; L Z Rassenti; T J Kipps; F Caligaris-Cappio; M Kneba; J C Byrd; M J Hallek; E Montserrat; P Hillmen
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

8.  Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Thomas Lin; Susan M Geyer; Clive S Zent; Nelson Leung; Brian Kabat; Deborah Bowen; Michael R Grever; John C Byrd; Neil E Kay
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

9.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Kirsten Fischer; Paula Cramer; Raymonde Busch; Sebastian Böttcher; Jasmin Bahlo; Jöerg Schubert; Karl H Pflüger; Silke Schott; Valentin Goede; Susanne Isfort; Julia von Tresckow; Anna-Maria Fink; Andreas Bühler; Dirk Winkler; Karl-Anton Kreuzer; Peter Staib; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Barbara F Eichhorst; Michael Hallek; Stephan Stilgenbauer; Clemens-Martin Wendtner
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

10.  Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.

Authors:  Paolo Strati; William Wierda; Jan Burger; Alessandra Ferrajoli; Constantine Tam; Susan Lerner; Michael J Keating; Susan O'Brien
Journal:  Cancer       Date:  2013-08-13       Impact factor: 6.860
View more
  9 in total

Review 1.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 2.  Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data.

Authors:  Anna Maria Frustaci; Alessandra Tedeschi; Paola Picardi; Maddalena Mazzucchelli; Roberto Cairoli; Marco Montillo
Journal:  Ther Adv Hematol       Date:  2016-05-21

Review 3.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

Review 4.  Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia.

Authors:  Anna Maria Frustaci; Alessandra Tedeschi; Paola Picardi; Roberto Cairoli; Marco Montillo
Journal:  Biologics       Date:  2015-09-18

Review 5.  The Inside Story of Adenosine.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Maria Grazia Tozzi
Journal:  Int J Mol Sci       Date:  2018-03-09       Impact factor: 5.923

Review 6.  Current trials for frontline therapy of mantle cell lymphoma.

Authors:  Raphael E Steiner; Jorge Romaguera; Michael Wang
Journal:  J Hematol Oncol       Date:  2018-01-27       Impact factor: 17.388

Review 7.  Emerging Role of Purine Metabolizing Enzymes in Brain Function and Tumors.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Edoardo Petrotto; Maria Grazia Tozzi
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

Review 8.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

9.  Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Authors:  Alessandra Tedeschi; Anna Maria Frustaci; Francesca Romana Mauro; Annalisa Chiarenza; Marta Coscia; Stefania Ciolli; Gianluigi Reda; Luca Laurenti; Marzia Varettoni; Roberta Murru; Claudia Baratè; Paolo Sportoletti; Antonino Greco; Chiara Borella; Valentina Rossi; Marina Deodato; Annalisa Biagi; Giulia Zamprogna; Angelo Curto Pelle; Gianfranco Lapietra; Candida Vitale; Francesca Morelli; Ramona Cassin; Alberto Fresa; Chiara Cavalloni; Massimiliano Postorino; Claudia Ielo; Roberto Cairoli; Francesco Di Raimondo; Marco Montillo; Giovanni Del Poeta
Journal:  Blood Adv       Date:  2021-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.